On September 23, 2024, BioVie Inc., a clinical-stage biopharmaceutical company, announced the entry into a placement agent agreement with ThinkEquity LLC for a public offering of shares and warrants. The offering includes up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to buy additional shares. The gross proceeds are expected to be approximately $3 million before fees and expenses. The offering, made under BioVie's effective registration statement on Form S-3, is expected to close on September 25, 2024. The company plans to use the net proceeds for working capital and general corporate purposes. BioVie also issued a warrant to the placement agent, exercisable for 98,040 shares at $1.9125 per share. The announcement was accompanied by press releases detailing the offering and its pricing. BioVie specializes in developing treatments for advanced liver disease and neurological disorders, with drug candidates NE3107 for neurodegenerative diseases and BIV201 for liver cirrhosis.

On September 23, 2024, BioVie Inc., a clinical-stage biopharmaceutical company, announced the entry into a placement agent agreement with ThinkEquity LLC for a public offering of shares and warrants. The offering includes up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to buy additional shares. The gross proceeds are expected to be approximately $3 million before fees and expenses. The offering, made under BioVie's effective registration statement on Form S-3, is expected to close on September 25, 2024. The company plans to use the net proceeds for working capital and general corporate purposes. BioVie also issued a warrant to the placement agent, exercisable for 98,040 shares at $1.9125 per share. The announcement was accompanied by press releases detailing the offering and its pricing. BioVie specializes in developing treatments for advanced liver disease and neurological disorders, with drug candidates NE3107 for neurodegenerative diseases and BIV201 for liver cirrhosis.